Home

PABLO J CAGNONI

CIK 1205703 · President, Global Head of R&D · last filed 2026-08-20

PABLO J CAGNONI is a President, Global Head of R&D who has filed 57 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing shows the insider sold $1.4M of INCY on Aug 20, 2026. Across all open-market trades the lifetime net is −$14.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $22.9M across reported positions. 28 SEC filings were submitted jointly with INCYTE CORP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$22.91M

Companies

7

Total Filings

57

Lifetime Open-Market Net

-$14.37M

Filer Profile

Reported Address
ONYX PHARMACEUTICALS, INC.
249 E. GRAND AVE.
SOUTH SAN FRANCISCO, CA 94080
Related Filers
INCYTE CORP — 28 joint filings, latest 2026-08-20
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
INCY President, Global Head of R&D 183,200 $122.87 $22.51M -$12.61M 21 2026-08-20
Fusion Pharmaceuticals Inc. (FUSN) Delisted Director — $21.55 — $0 5 2024-06-04
Rubius Therapeutics, Inc. (RUBY) Delisted CEO and President 66,082 $0.08 $5.5K $50.6K 8 2023-02-01
CRSP Director 7,500 $53.33 $399.9K -$1.73M 6 2019-11-21
CRISPR Therapeutics AG (PZRX) Delisted Director — — — $0 2 2017-06-02
ONYX PHARMACEUTICALS INC (ONXX) Delisted EVP, Global R&D and Tech Ops 16,257 — — $0 1 2013-03-13
ALLOS THERAPEUTICS INC (ALTH) Delisted Sr. VP, Chief Medical Officer 25,200 — — -$73.3K 6 2009-10-02

Recent Filings

57 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-20 INCY Sell (S) −10,801 -$1.36M EDGAR
2026-08-19 INCY Notice (144) −10,801 -$1.36M EDGAR
2026-08-14 INCY Sell (S) −10,803 -$1.30M EDGAR
2026-08-12 INCY Notice (144) −10,803 -$1.30M EDGAR
2026-08-07 INCY Sell (S) −10,640 -$1.31M EDGAR
2026-08-07 INCY Sell (S) −10,640 -$1.31M EDGAR
2026-08-05 INCY Notice (144) −10,640 -$1.31M EDGAR
2026-08-04 INCY Sell (S) −15,888 -$1.90M EDGAR
2026-07-31 INCY Notice (144) −15,888 -$1.90M EDGAR
2026-07-20 INCY Grant (A) +13,403 $0 EDGAR
Showing 1–10 of 57
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.